What Is the BTAL ETF? Complete Guide to Returns, Fees, Holdings, and Alternative ETFs
The AGF U.S. Market Neutral Anti-Beta ETF (BTAL) combines long positions in low-beta stocks with short positions in high-beta stocks. Its annual distribution, anti-beta structure, and differences in strategy and exposure from DYNF, THRO, and JMEE are key selection criteria.
What Is the AGF U.S. Market Neutral Anti-Beta ETF?
This is a market-neutral ETF that buys low-volatility, low-beta stocks and sells high-volatility, high-beta stocks. By combining these two positions, it seeks to perform in the opposite direction to the broader market.
It may suit investors seeking a hedge against market declines or exposure with a lower correlation to equities.
This ETF is passively managed by AGF to track a market-neutral index.
How Does the AGF U.S. Market Neutral Anti-Beta ETF Invest?
| Item | Details |
|---|---|
| Investment Approach | Buy low-beta stocks + short high-beta stocks |
| Management Style | Passive (market-neutral index) |
| Strategy | Anti-beta hedge |
| Distribution Schedule | Annual distribution |
| Total Expense Ratio | 1.40% |
The ETF buys low-beta stocks while selling high-beta stocks of equivalent size to offset the broader market's directional movement. During market declines, the short high-beta position tends to generate gains and provide a hedge, but the strategy may underperform during strong market advances.
- Combines long low-beta positions with short high-beta positions
- Tends to move in the opposite direction to the market
AGF U.S. Market Neutral Anti-Beta ETF Assets and Fees (AUM and Expense Ratio)
Assets under management (AUM) stand at $334.7M, with a total expense ratio of 1.40% per year.
The primary point of comparison with equity ETFs that are directly exposed to market direction is its hedge-oriented tendency to move in the opposite direction to the market.
AGF U.S. Market Neutral Anti-Beta ETF Performance and Fund Flows
The performance of an anti-beta strategy depends on market volatility and beta dispersion. It tends to outperform during sharp market declines as the short high-beta position generates gains, but underperform during strong market advances. Its hedging effect becomes more pronounced when volatility rises.
Fund flows into and out of anti-beta products vary with market volatility, demand for hedges, and investor risk sentiment. These products may attract inflows as hedging vehicles when market uncertainty increases. Performance can also vary significantly depending on market direction and the volatility environment.
Pros and Cons of the AGF U.S. Market Neutral Anti-Beta ETF
Its ability to hedge against market declines is a key strength, while underperformance in bull markets, strategy complexity, and potential inefficiency as a long-term holding are important considerations.
💪 Key Advantages
⚠️ Key Risks
AGF U.S. Market Neutral Anti-Beta ETF Alternatives and Related Products
For factor-rotation exposure, DYNF is a potential direct alternative. For thematic-rotation exposure, products such as THRO may also be considered. Investors seeking enhanced exposure to small- and mid-cap equities may also evaluate products such as JMEE. DYNF, THRO, and JMEE are all directional equity strategies that differ in nature from this market-neutral hedge, while BTAL stands apart through its anti-beta structure of long low-beta positions and short high-beta positions.
| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
| iShares U.S. Equity Factor Rotation Active ETF | $67.35 | -2.0% | $42.7B | 0.26% | 0.83% | +11.1% | |
| iShares U.S. Thematic Rotation Active ETF | $43.05 | -2.1% | $7.5B | 0.57% | 0.3% | +11.6% | |
| ARK Innovation ETF | $80.75 | -6.1% | $6.5B | 0.75% | - | -5.8% | |
| JPMorgan Small & Mid Cap Enhanced Equity ETF | $74.81 | -1.3% | $3.0B | 0.24% | 0.97% | +18.7% | |
| Principal U.S. Small-Cap ETF | $68.37 | -1.7% | $2.8B | 0.38% | 0.59% | +21.2% |
| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| TPG Inc | - | $46.68 | -2.6% | $17.9B | 53.7 | 5.03% | |
| OKTA | Okta Inc | 0.01% | $208.24 | -6.1% | $36.4B | 125.8 | - |
| Molina Healthcare Inc | 0.01% | $204.78 | +2.9% | $10.7B | - | - | |
| CAH | Cardinal Health Inc | 0.01% | $250.48 | -0.2% | $58.0B | 34.6 | 0.83% |
| Rivian Automotive Inc | 0.01% | $12.16 | +6.2% | $17.6B | - | - | |
| ABBV | Abbvie Inc | 0.01% | $294.89 | +1.4% | $521.1B | 83.4 | 2.32% |
| CF Industries Holdings Inc | 0.01% | $123.30 | +4.4% | $18.7B | 9.2 | 1.76% | |
| Murphy USA Inc | 0.01% | $534.95 | -0.9% | $9.8B | 15.0 | 0.48% | |
| Simpson Manufacturing Co Inc | 0.00% | $193.34 | -1.1% | $7.9B | 20.9 | 0.61% | |
| TDY | Teledyne Technologies Inc | 0.00% | $658.23 | -2.8% | $30.3B | 30.1 | - |
AGF U.S. Market Neutral Anti-Beta ETF Investor Checklist
Review these points before investing in BTAL. Its market-downside hedge is a potential attraction, but investors should first assess its underperformance in bull markets, strategy complexity, and potential inefficiency as a long-term holding. It is also advisable to compare it with directional equity products.
| Checkpoint | What to Review | Current Status |
|---|---|---|
| 🛡️ Hedge Characteristics | Assess downside protection during market declines | Anti-beta |
| 📉 Bull-Market Underperformance | Assess performance during strong market advances | Possible underperformance |
| 🔗 Correlation | Assess its tendency to move in the opposite direction to the market | Relatively low |
| 🧮 Strategy Understanding | Understand the long-short structure | Review required |
Losses during strong market advances and underperformance when beta dispersion narrows are key performance variables, while the long-short structure can make results less intuitive to assess. Because the fund is designed as a hedge, holding it alone over an extended period may be inefficient.
BTAL may be a potential fit for investors seeking a hedge against market declines or exposure with a lower correlation to equities. Investors seeking directional equity exposure may compare products such as DYNF and THRO, while those seeking an anti-beta hedge may evaluate BTAL alongside those alternatives.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 10, 2026.